Across TCGA pan-cancer cohorts, RPL32P35 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RPL32P35 data layer.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RPL32P35 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL32P35 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LAML show a favorable association.
CESC, STAD, and READ are the cancer types where RPL32P35 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.